

January 18, 2019

Indices					
India	Jan 17	1D% Chge	1M% Chge	3M% Chge	PE*
<b>S&amp;P BSE Sensex</b>	36374.08	0.15	0.29	4.58	23.96
<b>Nifty 50</b>	10905.20	0.14	0.15	4.33	26.21

\*Trailing PE

Global	Jan 17	1D% Chge	1M% Chge	3M% Chge
<b>DJIA</b>	24370.10	0.67	3.29	-5.20
<b>Nasdaq</b>	7084.46	0.71	4.90	-7.30
<b>Nikkei 225</b>	20402.27	-0.20	-5.14	-10.68
<b>Straits Times</b>	3214.44	-0.45	3.22	4.67
<b>Hang Seng</b>	26755.63	-0.54	2.56	5.08
<b>FTSE 100</b>	6834.92	-0.40	0.91	-3.11

Rs. Cr	FII Inv (Equity)		MF Inv (Equity)	
	Jan 16		Jan 16	
<b>Buy</b>	3928.07		2115.98	
<b>Sell</b>	3999.1		1873.28	
<b>Net</b>	-71.03		242.70	

FII Derivative Trade Statistics – Jan 16			
(Rs cr)	Buy	Sell	Open Interest
<b>Index Futures</b>	2990.25	3808.33	37656.73
<b>Index Options</b>	82558.87	82193.30	62031.92
<b>Stock Futures</b>	11383.20	11212.03	85380.87
<b>Stock Options</b>	6811.92	6856.21	9648.46

Debt Watch	Jan 17	Jan 16
<b>Call Rate</b>	6.45%	6.40%
<b>10 Yr Gilt</b>	7.55%	7.56%
<b>3-mth CP rate</b>	7.75%	7.85%
<b>1-yr CP rate</b>	8.70%	8.65%
<b>3-mth CD rate</b>	7.23%	7.23%
<b>12-mth CD rate</b>	7.75%	7.75%
<b>5 yr Corp Bond</b>	8.20%	8.24%
<b>Net LAF o/s (Rs Cr)</b>	3,141*	-1,992
<b>G-sec Volume (Rs Cr)</b>	24210	36835

\*Data pertains to the LAF Repo auction

Currencies Vs INR		
	Jan 17	Jan 16
<b>USD</b>	71.04	71.24
<b>GBP</b>	91.58	91.63
<b>Euro</b>	81.00	81.16
<b>100 Yen</b>	65.28	65.46

Commodity Prices	Jan 17	1W% Chge	1M% Chge	1Y% Chge
<b>NYMEX Crude Oil (\$/bbl)</b>	52.07	-0.99	4.39	-18.60
<b>Gold (Rs/10 gm)#</b>	32488	1.16	3.70	7.72

#NCDEX Spot Prices

New Fund Offers		
Scheme	Open Date	Close Date
<b>Debt Funds</b>		
SBI Debt Fund Series C – 38 (1224 days)	15-Jan-19	22-Jan-19
<b>Hybrid Funds</b>		
NA	NA	NA
<b>Equity Funds</b>		
NA	NA	NA

### Indian Equity

- Indian equity indices ended marginally higher on Thursday after gains in financial and information technology stocks were offset by losses in pharmaceutical counters.
- Investors remained cautious intraday in the midst of the corporate earnings season.
- Shares of HDFC, HCL Tech, TCS, and Tech Mahindra advanced 0.8-1.8%.
- Shares of Sun Pharma emerged the biggest laggard on the Nifty 50 – down 6%.

### Indian Debt

- The interbank call money rate ended at 6.45% on Thursday as against 6.40% on Wednesday.
- Gilt prices ended marginally higher on Thursday on short covering.
- Intraday, investor concerns about India's fiscal situation put prices under pressure.
- The yield of the 10 year benchmark 7.17% 2028 paper ended at 7.55% on Thursday as against 7.56% on Wednesday.

### Global Indices

- Straits Times** index fell on Thursday due to decline in the country's non-oil exports in December.
- Nikkei** index ended slightly lower on Thursday as stronger yen pulled down exporters' shares.
- Hang Seng** index ended lower on Thursday as investors remained wary ahead of the release of the China's growth figures.
- FTSE** index ended down on Thursday as political uncertainty continued to weigh on sentiment.
- Dow Jones** ended higher on Thursday on the back of rise in health care and industrial stocks.

### Capital Market

- SBI raises \$1.25 bn via dollar bond sale.
- Jet Airways Chairman Naresh Goyal tells the SBI that he is ready to invest up to Rs 700 cr in the airline on the condition that his stake does not fall below 25%.
- UCO Bank board approves raising Rs 1,000 cr via QIP.
- Larsen & Toubro Infotech acquires Ruletronics for \$7.48 mn.
- SoftBank to pick up 42% in FirstCry for \$400 mn.
- Dailyhunt raises Rs 24.61 cr from Omidyar and Sequoia.
- IIFL AMC raises Rs 950 cr Category II AIF, targets up to Rs 1100 cr corpus.
- Power Finance Corporation (PFC) to borrow Rs 14000 to fund Rural Electrification Corporation (REC).
- BHEL to set up electric vehicle charging points on Delhi-Chandigarh highway.
- Adani Group announces a joint venture with German major BASF SE worth Rs 16000 cr for manufacturing plants of acrylic value chain at the former's Mundra port in Gujarat.
- Parag Milk Foods will supply 10,000 litres of premium cow milk in the Delhi-NCR market daily by airlifting from its dairy farm near Pune.
- Aurobindo Pharma acquires seven marketed oncology injectable products from Spectrum Pharmaceuticals for about \$300 mn.

### Regulatory

- Upstream regulator DGH says government has deferred for the second time the deadline for submission of bids in the auction of 25 oil and gas fields that hold resources worth an estimated Rs 1 lakh cr.

### Government

- India Ratings and Research says India's growth is likely to stay the course and may come in slightly higher in 2019-20 than 2018-19.
- Prime Minister Narendra Modi launches global trade show at Vibrant Gujarat Summit.
- Finance Minister Arun Jaitley says budget content will be decided by economic realities.
- Government plans to create a business enterprise register that will have details of all kind of businesses being run in the country as it gears up to conduct a nationwide economic census in 2019-20.
- Government is mulling introduction of a procedure of "deemed admission" of companies under the Insolvency and Bankruptcy Code (IBC).

### International

- US Philly Fed said its index for current manufacturing activity jumped to 17.0 in January from 9.1 in December.
- US initial jobless claims edged down to 213,000, a decrease of 3,000 from the previous week's unrevised level of 216,000.
- Eurozone construction output declined a seasonally-adjusted 0.1% month-on-month in

November, after a 1.6% contraction in October.

- Eurozone consumer price index rose 1.6% in December year-on-year following a 1.9% increase in November.
- Japan's overall CPI rises 0.3% on year in December following 0.8% rise in November.

**Source: CRISIL Research**

*Disclaimer - CRISIL Research, a division of CRISIL Limited (CRISIL) has taken due care and caution in preparing this Report based on the information obtained by CRISIL from sources which it considers reliable (Data). However, CRISIL does not guarantee the accuracy, adequacy or completeness of the Data / Report and is not responsible for any errors or omissions or for the results obtained from the use of Data / Report. This Report is not a recommendation to invest / disinvest in any entity covered in the Report and no part of this report should be construed as an investment advice. CRISIL especially states that it has no financial liability whatsoever to the subscribers/ users/ transmitters/ distributors of this Report. CRISIL Research operates independently of, and does not have access to information obtained by CRISIL's Ratings Division / CRISIL Risk and Infrastructure Solutions Limited (CRIS), which may, in their regular operations, obtain information of a confidential nature. The views expressed in this Report are that of CRISIL Research and not of CRISIL's Ratings Division / CRIS. No part of this Report may be published / reproduced in any form without CRISIL's prior written approval. CRISIL or its associates may have commercial transactions with the company/entity.*